Investigation of gene expression and secretion of P53, LIF, IL_10, IL-17 after administration of tacrolimus in endometrial and uterine fluid in patients with repeated implantation failure: Clinical trial

Shahid Beheshti University of Medical Sciences0 个研究点目标入组 10 人开始时间: 待定最近更新: 2018年2月22日

适应症

试验速览

暂无简介。

•History of 3 or more failed IVF/ET cycles with morphologically and developmentally average to good-quality embryo( 7 or more blastomeres and less than 10% fragmentation in day 3 ) into an adequately prepared endometrium (endometrial thickness equal or more than 8 mm); Women who had regular menses (25 to 35 days); Women who had normal karyotype;
•women who had at least one of these Immunological disorders in their peripheral blood sample between day of 5 to 10 of menstrual cycle: IFN-g/IL-4 equal or more than 10.3 or Nk-cell percentage greater than 12%

•Present of sub mucosal fibroids, endometrial polyps, intrauterine adhesions, congenital anomalies of uterus or hydrosalpinges
•History of active autoimmune disease (With assessment of ANA, Anti-TG, Anti-TPO, Anti-dsDNA); Women with acquired or inherited thrombophilia (With assessment of Factor2, Factor5, Factor 8, Fibrinogen, Anti- Cardiolipin, Anti-Phospholipid Antibody, Lupus Anti-Coagulate, s-MTHFR gene)
•Pregnant women; History of miscarriage in a former IVF/ET cycle; Women who received vaccine in the last three months; Women who received steroid hormones in the last 2 months; Women receiving immunotherapy; Women with chronic inflammatory diseases

发起方